Nexus Conference’s Post

Interested in learning how to optimize your SAD and MAD studies? Attend my team member’s presentation at BioPharma Clinical Trials to learn about past lessons learned and a glimpse into future trends for these early phase studies! https://bit.ly/4dlFVhI

Interested in learning how to optimize your SAD and MAD studies? Attend my team member’s presentation at BioPharma Clinical Trials to learn about past lessons learned and a glimpse into future trends for these early phase studies! https://bit.ly/4dlFVhI

Interested in learning how to optimize your SAD and MAD studies? Attend my team member’s presentation at BioPharma Clinical Trials to learn about past lessons learned and a glimpse into future trends for these early phase studies! https://bit.ly/4dlFVhI

Interested in learning how to optimize your SAD and MAD studies? Attend my team member’s presentation at BioPharma Clinical Trials to learn about past lessons learned and a glimpse into future trends for these early phase studies! https://bit.ly/4dlFVhI

Interested in learning how to optimize your SAD and MAD studies? Attend my team member’s presentation at BioPharma Clinical Trials to learn about past lessons learned and a glimpse into future trends for these early phase studies! https://bit.ly/4dlFVhI

Interested in learning how to optimize your SAD and MAD studies? Attend my team member’s presentation at BioPharma Clinical Trials to learn about past lessons learned and a glimpse into future trends for these early phase studies! https://bit.ly/4dlFVhI

🌍 Clinical Trials Day 🌍 Today, May 20th, is Clinical Trials Day, a time to pause in reflection, recognition, and admiration of all that has been accomplished thanks to clinical trials and the people behind them. At Verbatim Pharma, we are proud to support the clinical trials sector by connecting talented professionals with these organizations. Join us in acknowledging the significance of clinical trials and their impact on global health #WorldClinicalTrialsDay #ClinicalTrials #MedicalResearch #VerbatimPharma

Some interesting insights from the Q&A with Ken Song regarding RayzeBio's journey: 1. Quick Rise to Acquisition: RayzeBio swiftly progressed from Series A to acquisition within a remarkably short timeframe, showcasing effective strategic decision-making and capital deployment. 🚀 2. Navigating Funding Challenges: Despite facing a challenging fundraising environment, RayzeBio demonstrated resilience and strategic foresight by prioritizing proper capitalization over short-term concerns about dilution. 💡 Maintaining Discipline: Throughout the IPO process, RayzeBio remained disciplined, resisting the temptation to maximize gains and ensuring a successful debut on the stock market. 📉 3. Post-IPO Interest and Acquisition: Interestingly, RayzeBio garnered substantial acquisition interest only after going public, indicating that the IPO served as a catalyst for attracting strategic partners. 🔄 4. Future of Radiopharmaceuticals: Song envisions radiopharmaceuticals evolving into a major modality, with increased commitment from pharmaceutical companies and advancements in isotope availability driving further innovation. 🧪 RayzeBio's journey offers valuable insights into biotech entrepreneurship, strategic decision-making, and the evolving landscape of pharmaceutical innovation. 🌱

This STAT piece is right that clin trials struggle to achieve pt centricity, but only partially right about reason (outdated tech to manage processes). Also key factors: tension between push for simplicity/minimalism (eg Recovery study) and value of collecting potentially exceptionally valuable and rare information/data from actual people (as I recently discussed on LI w/ Kim Branson in context of his recent podcast interview w/Vijay Pande, PhD). Another factor: skittishness (we'll call it) of companies in disclosing entry criteria and other trial info helpful for patients, as poignantly shared by Bess Stillman, M.D., as I've discussed here: https://lnkd.in/eWBFX4gK . cc Amy Abernethy who I'm sure had great additional perspective on these challenges...

CALLING THE COMPANION DIAGNOSTIC COMMUNITY Companion diagnostic regulation is critically challenging biopharma due to Europe's IVDR confusion, uncertainty about LDT reclassification, and fear around upcoming FDA updates. This summer, there’s one essential event to navigate these global regulatory changes, tackle reimbursement and policy issues, reduce submission risks, and ensure timely access to safe and effective companion diagnostics worldwide. Secure your spot in the room now at the World CDx Regulatory Affairs & Policy Summit to make sure you have a role in collaborating with key decision makers, influencing the policies that will shape CDx regulation & reimbursement indefinitely: https://ter.li/j2phi9 Jai Pandey, PhD, Vihanga Pahalawatta, Lori Roadcap, Andrea Renninger, Claudia Dollins Mary J. Savage, Deb Rasmussen, Ralph Riley, Dun Liang, Andrew L'Huillier, Sid Mathur, Qing Li, MD. PhD, Hannah O. Edward, Kaska (Katarzyna) Kowanetz, PhD, RAC, Brian Baker